8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):  November 11, 2010

Interleukin Genetics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-32715	94-3123681
(Commission File Number)	(IRS Employer Identification No.)
135 Beaver Street Waltham, MA	02452
(Address of Principal Executive Offices)	(Zip Code)

(781) 398-0700

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02 Results of Operations and Financial Condition.

On November 11, 2010, Interleukin Genetics, Inc. issued a press release and held a conference call to report its financial and operational results for the third quarter ended September 30, 2010. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and a copy of a transcript of portions of the conference call is attached as Exhibit 99.2, and each is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press Release dated November 11, 2010.
99.2	Transcript of Portions of Conference Call Held on November 11, 2010.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Interleukin Genetics, Inc.
	(Registrant)
Date: November 11, 2010	/s/ ELIOT M. LURIER
	Eliot M. Lurier
	Chief Financial Officer
	(Signature)

EX-99.1

Exhibit 99.1

Interleukin Genetics Reports Third Quarter 2010 Financial Results

WALTHAM, MA — November 11, 2010 - Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for the third quarter ended September 30, 2010.

Revenue for the three months ended September 30, 2010 was $0.5 million compared to $0.3 million for the same period in the prior year. The increase was primarily attributable to greater genetic test revenue as we experience positive growth.

Research and development expenses were $0.4 million for the three months ended September 30, 2010 compared to $0.9 million for the same period in the prior year. The decrease is primarily attributable to lower clinical trial expenses, compensation and patent portfolio related expenses.

Selling, general and administrative expenses were $1.1 million for the three months ended September 30, 2010, compared to $1.7 million for same period in the prior year. The decrease was primarily attributable to lower product development and advertising costs associated with our Inherent Health™ brand of genetic tests incurred in the rollout of these tests in 2009 and lower administrative consulting and compensation expenses.

The Company reported a net loss from continuing operations of $1.4 million, or $(0.04) per basic and diluted common share, for the third quarter of 2010, compared to a loss from continuing operations of $2.6 million, or $(0.08) per basic and diluted shares for the same period in the prior year. On September 30, 2010, the Company had cash and cash equivalents of $5.2 million.

“We are pleased to show continued revenue driven by our Weight Management genetic test and sales of our new Wellness Select combination product,” said Lewis H. Bender, CEO, Interleukin Genetics, Inc. “We are encouraged by the data from clinical programs we have undertaken in the fields of obesity, osteoarthritis and periodontal disease, and look forward to generating results for increased distribution and insurance reimbursement for certain genetic tests.”

3rd Quarter Clinical Research Highlights

Periodontal Disease

The Company announced in August 2010 it would begin a 4,000 patient landmark clinical study with the University of Michigan and Renaissance Health Service Corporation that will evaluate risk factors predictive of periodontal disease progression to tooth loss using a new version of Interleukin Genetics’ PST genetic test.  The clinical study conduced with the University of Michigan and sponsored by Renaissance Health Services is using a large dental claims database and is designed to test whether risk factors, including genetic information, can guide more successful intervention and thus reduce the adverse outcomes of periodontal disease, such as tooth loss.

Osteoarthritis

The Company announced in September 2010 findings with the Thurston Arthritis Research Center at the University of North Carolina at Chapel Hill from a large clinical study to evaluate the role of genetic factors in osteoarthritis progression. The study showed patients with radiographic evidence of knee osteoarthritis who inherited a specific pattern of genetic variations in the interleukin-1 receptor antagonist (IL-1Ra) gene were almost twice as likely to progress to severe disease as other patients and validated results from a previously announced clinical study. Results from the second study, which followed 1,154 patients for up to 11 years, were presented at the fall World Congress on Osteoarthritis in Brussels, Belgium.

Conference Call and Webcast Information

InterleukinGenetics will host a live conference call and webcast today at 4:30 p.m. EST to review the Company’s new business developments and third quarter financial results.  To access the live call, dial (877) 324-1976 (domestic) or (631) 291-4550 (international). The live webcast and replay access will be available on the Investors section of the Company’s website at http://www.ilgenetics.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand.  The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. Interleukin Genetics’ flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Act (CLIA).  For more information please visit www.ilgenetics.com.

Certain statements contained herein are “forward-looking” statements, including statements regarding the potential forincreased distribution and insurance reimbursement for certain genetic tests.  Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company’s  annual report on Form 10-K for the year ended December 31, 2009 and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.

INTERLEUKIN GENETICS, INC.

FINANCIAL HIGHLIGHTS

Balance Sheet Data :	September 30,			December 31,
	2010			2009
	(Unaudited)
Cash and cash equivalents	$	5,202,022		$	906,248
Total current assets	$	5,823,257		$	1,315,991
Total assets	$	7,138,868		$	3,069,463
Total current liabilities	$	1,665,153		$	1,834,091
Total liabilities	$	12,665,153		$	8,834,091
Total shareholders' deficit	$	(5,526,285	)	$	(5,764,628	)
Total liabilities and shareholders' deficit	$	7,138,868		$	3,069,463

Statement of Operations Data (Unaudited):	Three Months Ended September 30,						Nine Months Ended September 30,
	2010			2009			2010			2009
Revenue:
Genetic testing service revenue	$	531,151		$	119,309		$	1,460,601		$	352,130
Contract research revenue		-			198,203			-			520,935
Other		13,593			5,370			25,805			20,274
Total revenue		544,744			322,882			1,486,406			893,339
Cost of revenue		409,010			305,303			1,254,033			912,150
Gross profit (loss)		135,734			17,579			232,373			(18,811	)
Operating costs and expenses:
Research and development		427,407			873,195			1,428,523			2,628,943
Selling, general and administrative		1,058,062			1,660,235			3,840,806			4,473,860
Amortization of intangibles		28,863			28,863			86,590			86,590
Total operating expenses		1,514,332			2,562,293			5,355,919			7,189,393
Loss from operations		(1,378,598	)		(2,544,714	)		(5,123,546	)		(7,208,204	)
Total other income and (expense), net		(63,545	)		(40,219	)		(177,371	)		(98,458	)
Loss from continuing operations
before income taxes		(1,442,143	)		(2,584,933	)		(5,300,917	)		(7,306,662	)
Income taxes		-			-			-			-
Loss from continuing operations	$	(1,442,143	)	$	(2,584,933	)	$	(5,300,917	)	$	(7,306,662	)
Income (loss) from discontinued operations,
net of income taxes		-			40,661			482,530			(1,405,214	)
Net loss	$	(1,442,143	)	$	(2,544,272	)	$	(4,818,387	)	$	(8,711,876	)
Basic and diluted net loss per
common share from:
Continuing operations	$	(0.04	)	$	(0.08	)	$	(0.15	)	$	(0.23	)
Discontinued operations		0.00			0.00			0.01			(0.04	)
Net loss	$	(0.04	)	$	(0.08	)	$	(0.14	)	$	(0.27	)
Weighted average common shares outstanding,
basic and diluted		36,545,747			32,059,258			35,410,705			31,975,953

#  #  #

Contacts:

Erin Walsh

Interleukin Genetics

781-419-4707

ewalsh@ilgenetics.com

EX-99.2

  
    Unassociated Document